In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scynexis, Inc.

http://www.scynexis.com/

Latest From Scynexis, Inc.

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Financing Business Strategies

November Gloom? US FDA’s Goal Dates Include Hard Calls On Ferring Rebyota, Y-mAbs’ Omblastys

November should see FDA action on what could be the first standardized fecal microbiota transplant product, rare cancer therapies from Y-mAbs and Spectrum, uniQure/CSL’s hemophilia B gene therapy and Provention Bio’s biologic to delay type 1 diabetes.

US FDA Performance Tracker Drug Review

F2G Plans Orphan Drug Strategy With Novel Antifungal

Olorofim employs a novel mechanism of action within the antifungal space and was tested in patients with high mortality risk who had exhausted treatment options.

Clinical Trials Business Strategies

Scynexis Switches Focus To Hospital Indications For Ibrexafungerp

With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.

Business Strategies Restructuring
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register